(Q24241431)

https://api.crossref.org/works/10.1002%2F14651858.CD006325.PUB2

Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006325.PUB2

Limb sparing versus amputation in osteosarcoma. Correlation between local control, surgical margins and tumor necrosis: Istituto Rizzoli experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006325.PUB2

Chemotherapy for the primary treatment of osteosarcoma: population effectiveness over 20 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006325.PUB2

High-dose methotrexate with citrovorum factor rescue and adriamycin in childhood osteogenic sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006325.PUB2

Response of osteogenic sarcoma to the combination of etoposide and cyclophosphamide as neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006325.PUB2

Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006325.PUB2

Competing risks analysis of patients with osteosarcoma: a comparison of four different approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006325.PUB2

Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006325.PUB2

Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006325.PUB2

Integration of modeling and simulation into hospital-based decision support systems guiding pediatric pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006325.PUB2

The role of pharmacokinetic and pharmacodynamic studies in the planning of protocols for the treatment of childhood cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006325.PUB2

A review of clinical and molecular prognostic factors in osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006325.PUB2

Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006325.PUB2

Methotrexate pharmacokinetics and prognosis in osteosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006325.PUB2

The role of methotrexate in osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006325.PUB2

Pharmacokinetic studies in children with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006325.PUB2

High-dose methotrexate in osteosarcoma: let the questions surcease--time for final acceptance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006325.PUB2

Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006325.PUB2

Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006325.PUB2

Preoperative chemotherapy for osteogenic sarcoma:Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006325.PUB2

Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006325.PUB2

Osteosarcoma of the limbs. Report of the EORTC-SIOP 03 trial 20781 investigating the value of adjuvant treatment with chemotherapy and/or prophylactic lung irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006325.PUB2

7 January 2021

Age and dose of chemotherapy as major prognostic factors in a trial of adjuvant therapy of osteosarcoma combining two alternating drug combinations and early prophylactic lung irradiation. French Bone Tumor Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006325.PUB2

7 January 2021

Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarter

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006325.PUB2

7 January 2021

A randomized study comparing high-dose methotrexate with moderate-dose methotrexate as components of adjuvant chemotherapy in childhood nonmetastatic osteosarcoma: a report from the Childrens Cancer Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006325.PUB2

7 January 2021

Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma. Analysis of the literature

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006325.PUB2

7 January 2021

Neoadjuvant chemotherapy for nonmetastatic osteosarcoma of the extremities: The recent experience at the Rizzoli Institute

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006325.PUB2

7 January 2021

A monocentric therapy study: An approach to optimize the results of the treatment of osteosarcoma by protocols based upon HDMTX, associated with systematic conservative surgery

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006325.PUB2

7 January 2021

Chemotherapy in osteogenic sarcoma: the experience of the Pediatric Department of the Gustave Roussy Institute

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006325.PUB2

7 January 2021

Osteosarcoma of the limb: An institutional report of 10 years experience with neoadjuvant chemotherapy and delayed surgery

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006325.PUB2

7 January 2021

Results of the COSS-77 and COSS-80 studies on adjuvant chemotherapy in osteosarcoma of the extremities

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006325.PUB2

7 January 2021

[Aggressive cytostatic treatment of osteogenic sarcoma in childhood (author's transl)]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006325.PUB2

7 January 2021

Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006325.PUB2

7 January 2021

The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006325.PUB2

7 January 2021

Osteogenic sarcoma: alterations in the pattern of pulmonary metastases with adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006325.PUB2

7 January 2021

A controlled pilot study of high-dose methotrexate as postsurgical adjuvant treatment for primary osteosarcoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006325.PUB2

7 January 2021

Comparison of intra-arterial cis-diamminedichloroplatinum II with high-dose methotrexate and citrovorum factor rescue in the treatment of primary osteosarcoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006325.PUB2

7 January 2021

Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006325.PUB2

7 January 2021

Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006325.PUB2

7 January 2021

Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. European Osteosarcoma Intergroup

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006325.PUB2

7 January 2021